Therapeutic cancer targeting peptides.

Antitumor monoclonal antibodies have shown clinical promise as cancer cell surface targeting agents. More tumor targeting antibodies are likely to be approved by the FDA in the next few years. However, there are two major limitations in antibody-targeted therapy: large size and nonspecific uptake of the antibody molecules by the liver and the reticuloendothelial system. These result in poor tumor penetration of antibody pharmaceuticals and dose-limiting toxicity to the liver and bone marrow. Peptides are excellent alternative targeting agents for human cancers, and they may alleviate some of the problems with antibody targeting. In the last decade, several investigators have successfully used combinatorial library methods to discover cell surface binding peptides that may be useful for cancer targeting. The phage-display library technique and the "one-bead one-compound" combinatorial library method are the two approaches that have been used. Cancer cell surface receptors or endothelial cell surface receptors of the neovasculature are the two popular therapeutic targets for cancer. Results from preclinical studies with some peptides are encouraging in their targeting potential.

[1]  R Pasqualini,et al.  Molecular addresses in blood vessels as targets for therapy. , 2001, Current opinion in chemical biology.

[2]  E. Ruoslahti,et al.  Molecular specialization of breast vasculature: A breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Frankel,et al.  Advances in immunotoxin biology and therapy: a summary of the Fourth International Symposium on Immunotoxins. , 1996, Cancer Research.

[4]  A. George,et al.  In vivo selection of sFv from phage display libraries. , 2000, Journal of immunological methods.

[5]  Wadih Arap,et al.  Biopanning and rapid analysis of selective interactive ligands , 2001, Nature Medicine.

[6]  P. Schatz,et al.  Screening for receptor ligands using large libraries of peptides linked to the C terminus of the lac repressor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Targeted delivery of multivalent phage display vectors into mammalian cells. , 1999, Biochimica et biophysica acta.

[8]  Jonathan A. Ellman,et al.  Design, Synthesis, and Evaluation of Small-Molecule Libraries , 1996 .

[9]  R. Houghten,et al.  The use of positional scanning synthetic peptide combinatorial libraries for the rapid determination of opioid receptor ligands. , 1993, Life sciences.

[10]  K. Lam,et al.  Treatment of B-cell lymphoma using peptides. A novel concept. , 1993, The Western journal of medicine.

[11]  H. Spring,et al.  Neuroblastoma tumor cell-binding peptides identified through random peptide phage display. , 2001, Cancer letters.

[12]  H. M. Geysen,et al.  Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Pellois,et al.  Peptide synthesis based on t-Boc chemistry and solution photogenerated acids. , 2000, Journal of combinatorial chemistry.

[14]  Erkki Ruoslahti,et al.  αv Integrins as receptors for tumor targeting by circulating ligands , 1997, Nature Biotechnology.

[15]  H. M. Geysen,et al.  Multi-pin peptide synthesis strategy for T cell determinant analysis. , 1990, Journal of immunological methods.

[16]  N. Oku,et al.  Suppression of tumor growth by novel peptides homing to tumor‐derived new blood vessels , 2002, FEBS letters.

[17]  D. Spencer,et al.  A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex. , 2001, Cancer research.

[18]  G. Clayman,et al.  Isolation of a peptide for targeted drug delivery into human head and neck solid tumors. , 2000, Cancer research.

[19]  J. Vose Immunotherapy for non-Hodgkin's lymphoma. , 2001, Oncology.

[20]  J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[21]  A. Eberle,et al.  Somatostatin analogs and radiopeptides in cancer therapy. , 2002, Biopolymers.

[22]  H. G. Wada,et al.  B-lymphoma cells are activated by peptide ligands of the antigen binding receptor or by anti-idiotypic antibody to induce extracellular acidification. , 1995, Cancer research.

[23]  K. Lam,et al.  Synthetic peptides inhibit adhesion of human tumor cells to extracellular matrix proteins. , 2001, Cancer research.

[24]  S. P. Fodor,et al.  Light-directed, spatially addressable parallel chemical synthesis. , 1991, Science.

[25]  Kit S. Lam,et al.  The “One-Bead-One-Compound” Combinatorial Library Method , 1997 .

[26]  R. Warnke,et al.  Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. , 1982, The New England journal of medicine.

[27]  E. Ruoslahti,et al.  A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells. , 2000, Cancer research.

[28]  W. Dower,et al.  Synthetic peptide ligands of the antigen binding receptor induce programmed cell death in a human B-cell lymphoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[29]  H. Dvorak,et al.  Penetration of Tumor Tissue by Antibodies and Other Immunoproteins , 1991, Annals of the New York Academy of Sciences.

[30]  R Pasqualini,et al.  NG2 proteoglycan-binding peptides target tumor neovasculature. , 1999, Cancer research.

[31]  Kim-Anh Do,et al.  Steps toward mapping the human vasculature by phage display , 2002, Nature Medicine.

[32]  Y. Chen,et al.  RGD-Tachyplesin inhibits tumor growth. , 2001, Cancer research.

[33]  R. Laskov,et al.  Studies on a naturally occurring human antibody active against mouse landschutz ascites tumor cells: I. Cytotoxicity assay system and quantitation in normal sera , 1968, International journal of cancer.

[34]  K. Lam,et al.  Identifying peptide ligands for cell surface receptors using cell-growth-on-bead assay and one-bead one-compound combinatorial library , 2002, Biotechnology Letters.

[35]  M. Kaminski,et al.  Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. , 1993, The New England journal of medicine.

[36]  L. Buhl,et al.  Surface immunoglobulin on B lymphocytes as a potential target for specific peptide ligands in chronic lymphocytic leukaemia , 2002, British journal of haematology.

[37]  G. Adams,et al.  Generating improved single-chain Fv molecules for tumor targeting. , 1999, Journal of immunological methods.

[38]  M. Linenberger,et al.  Mylotarg: antibody-targeted chemotherapy comes of age , 2001, Current opinion in oncology.

[39]  Timo Sorsa,et al.  Tumor targeting with a selective gelatinase inhibitor , 1999, Nature Biotechnology.

[40]  Fulvio Magni,et al.  Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) , 2000, Nature Biotechnology.

[41]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[42]  G. Denardo,et al.  Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. , 1997, Anticancer research.

[43]  R. Houghten,et al.  Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery , 1991, Nature.

[44]  Erkki Ruoslahti,et al.  Phage Libraries Displaying Cyclic Peptides with Different Ring Sizes: Ligand Specificities of the RGD-Directed Integrins , 1995, Bio/Technology.

[45]  V. Diehl,et al.  Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. , 1998, Blood.

[46]  R. Warnke,et al.  Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. , 1985, The New England journal of medicine.

[47]  H. Dvorak,et al.  Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. , 1991, Cancer cells.

[48]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[49]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[50]  M. Sussman,et al.  Maskless fabrication of light-directed oligonucleotide microarrays using a digital micromirror array , 1999, Nature Biotechnology.

[51]  E. Ruoslahti Targeting tumor vasculature with homing peptides from phage display. , 2000, Seminars in cancer biology.

[52]  E Ruoslahti,et al.  Solution structures and integrin binding activities of an RGD peptide with two isomers. , 2001, Biochemistry.

[53]  J. McGahan,et al.  Treatment of a Patient with b Cell Lymphoma by 1-131 Lym-1 Monoclonal Antibodies , 1987, The International journal of biological markers.

[54]  G. Denardo,et al.  Treatment of B cell malignancies with 131I LYM‐1 monoclonal antibodies , 1988, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[55]  M. Weitzman,et al.  Molecular adaptors for vascular-targeted adenoviral gene delivery. , 2000, Human gene therapy.

[56]  R Pasqualini,et al.  Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. , 2000, Cancer research.

[57]  G. Denardo,et al.  Radioimmunotherapy of lymphoma: a UC Davis experience. , 1995, Hybridoma.

[58]  J. Scott,et al.  Searching for peptide ligands with an epitope library. , 1990, Science.

[59]  C. Demangel,et al.  Identification of a peptide blocking vascular endothelial growth factor (VEGF)‐mediated angiogenesis , 2000, The EMBO journal.

[60]  I. Bernstein,et al.  Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas , 1995, The Lancet.

[61]  R. Jain,et al.  Delivery of Molecular and Cellular Medicine to Solid Tumors , 1997, Advanced drug delivery reviews.

[62]  G. Denardo,et al.  Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[63]  L. Cantley,et al.  The Phosphotyrosine Interaction Domain of SHC Recognizes Tyrosine-phosphorylated NPXY Motif (*) , 1995, The Journal of Biological Chemistry.

[64]  Wadih Arap,et al.  In vivo phage display and vascular heterogeneity: implications for targeted medicine. , 2002, Current opinion in chemical biology.

[65]  R. Barrett,et al.  Peptides on phage: a vast library of peptides for identifying ligands. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[66]  W. Dower,et al.  An in vitro polysome display system for identifying ligands from very large peptide libraries. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[67]  M. Weitzman,et al.  Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[68]  J. Wong,et al.  gamma-Interferon administration after 90yttrium radiolabeled antibody therapy: survival and hematopoietic toxicity studies. , 1995, International journal of radiation oncology, biology, physics.

[69]  S. A. Bush,et al.  Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  U. Stenman,et al.  Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. , 2000, European journal of biochemistry.

[71]  Candace S. Johnson,et al.  A Novel Approach for the Identification of Unique Tumor Vasculature Binding Peptides Using an E. coli Peptide Display Library , 2000, Annals of Surgical Oncology.

[72]  R. Beart,et al.  Incorporation of Tumor Vasculature Targeting Motifs into Moloney Murine Leukemia Virus Env Escort Proteins Enhances Retrovirus Binding and Transduction of Human Endothelial Cells , 2000, Journal of Virology.

[73]  E. Leproust,et al.  Digital light-directed synthesis. A microarray platform that permits rapid reaction optimization on a combinatorial basis. , 2000, Journal of combinatorial chemistry.

[74]  R. Frank Spot-synthesis: an easy technique for the positionally addressable, parallel chemical synthesis on a membrane support , 1992 .

[75]  G. P. Smith,et al.  Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. , 1988, Gene.

[76]  K. Lam,et al.  Targeted therapy for lymphoma with peptides. , 1997, Hematology/oncology clinics of North America.

[77]  S. Kennel,et al.  Labeling and distribution of linear peptides identified using in vivo phage display selection for tumors. , 2000, Nuclear medicine and biology.

[78]  I. Leigh,et al.  Isolation of human tumor-specific antibodies by selection of an antibody phage library on melanoma cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[79]  K. Lam,et al.  A new type of synthetic peptide library for identifying ligand-binding activity , 1992, Nature.

[80]  Wadih Arap,et al.  Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. , 2002, Cancer research.

[81]  H. Tsukada,et al.  Anti-neovascular therapy using novel peptides homing to angiogenic vessels , 2002, Oncogene.

[82]  Erkki Ruoslahti,et al.  Anti-cancer activity of targeted pro-apoptotic peptides , 1999, Nature Medicine.

[83]  Edward S. Kim,et al.  Epidermal growth factor receptor biology (IMC-C225) , 2001, Current opinion in oncology.

[84]  M. Sheets,et al.  Human scFv antibody fragments specific for the epithelial tumour marker MUC-1, selected by phage display on living cells , 2001, Cancer Immunology, Immunotherapy.

[85]  J. Devlin,et al.  Random peptide libraries: a source of specific protein binding molecules. , 1990, Science.

[86]  R. Warnke,et al.  Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: correlation with clinical responses. , 1987, Blood.

[87]  I. Bernstein,et al.  Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. , 1993, The New England journal of medicine.

[88]  Erkki Ruoslahti,et al.  Targeting the prostate for destruction through a vascular address , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[89]  F. Burrows,et al.  Vascular targeting--a new approach to the therapy of solid tumors. , 1994, Pharmacology & therapeutics.

[90]  M. Sioud,et al.  An Anti-leukemic Single Chain Fv Antibody Selected from a Synthetic Human Phage Antibody Library , 2001 .

[91]  K. Lam,et al.  Application of combinatorial library methods in cancer research and drug discovery. , 1997, Anti-cancer drug design.

[92]  M. Kaminski,et al.  Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  D. Baccanari,et al.  Peptide agonists of the thrombopoietin receptor , 1998, Stem cells.

[94]  W. Arap,et al.  Identification of receptor ligands with phage display peptide libraries. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[95]  Erkki Ruoslahti,et al.  Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature , 2001, Arthritis research.

[96]  R. Warnke,et al.  A clinical trial of anti-idiotype therapy for B cell malignancy. , 1985, Blood.

[97]  J. Engberg,et al.  Identification of patient‐specific peptides for detection of M‐proteins and myeloma cells , 1999, British journal of haematology.

[98]  Á. Furka,et al.  General method for rapid synthesis of multicomponent peptide mixtures. , 2009, International journal of peptide and protein research.

[99]  K. Lam,et al.  Peptide and small molecule microarray for high throughput cell adhesion and functional assays. , 2001, Bioconjugate chemistry.

[100]  V. Petrenko,et al.  Phage display selection of peptides that affect prostate carcinoma cells attachment and invasion , 2001, The Prostate.

[101]  P. Neumeister,et al.  Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate , 2001, Annals of Hematology.

[102]  Y. Gho,et al.  Arginine-rich Anti-vascular Endothelial Growth Factor Peptides Inhibit Tumor Growth and Metastasis by Blocking Angiogenesis* , 2000, The Journal of Biological Chemistry.

[103]  B L Hall,et al.  A novel tumor-specific human single-chain Fv selected from an active specific immunotherapy phage display library. , 1998, Immunotechnology : an international journal of immunological engineering.

[104]  R Pasqualini,et al.  Chemotherapy targeted to tumor vasculature. , 1998, Current opinion in oncology.